seattle genetics astellas collaboration
Seattle Genetics and Astellas are co-developing enfortumab vedotin-ejfv under a collaboration that was entered into in 2007 and expanded in 2009. Under the expanded collaboration, Agensys receives the right to obtain exclusive ADC licenses for multiple additional targets in exchange for payment of the upfront fee. Seattle Genetics and Agensys originally entered into the ADC collaboration in January 2007, under which the companies agreed to co-develop … Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. The FDA’s Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. - Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -. About Astellas Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Seattle Genetics Forward-Looking Statements Under … TOKYO and BOTHELL, Wash. -- September 18, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV ® (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. Seattle Genetics and Astellas are co-developing enfortumab vedotin under a collaboration that was entered into in 2007 and expanded in 2009. Seattle Genetics, Inc. and Astellas Pharma Inc.have announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate (ADC) enfortumab vedotin and Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), in patients with previously … Steady results as projected for the first year of Strategic Plan 2018. TOKYO and BOTHELL, Wash., February 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV ™ (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD … TOKYO and BOTHELL, Wash., February 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEV™ (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. "We look forward to further evaluating enfortumab vedotin and pembrolizumab in this high unmet need patient population.". Seattle Genetics Forward Looking Statements Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Padcev, from collaboration partners Astellas and Seattle Genetics, is a protein that delivers a dose of chemotherapy directly to tumor cells that present a … Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with … Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide. The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. Seattle Genetics and Astellas are co-developing PADCEV (enfortumab vedotin-ejfv) under a collaboration … You are now leaving www.astellas.com/us. Factors that may cause such a difference include the possibility that ongoing and subsequent clinical trials of enfortumab vedotin, including the proposed phase 3 trial of enfortumab vedotin in combination with pembrolizumab, may fail to establish sufficient efficacy; that adverse events or safety signals may occur; that adverse regulatory actions or other setbacks could occur as enfortumab vedotin advances in clinical trials even after promising results in earlier clinical trials; and that the Biologics License Application submission and any future potential supplemental Biologics License Application submissions for enfortumab vedotin may not be approved by the FDA in a timely manner or at all or with the requested label(s). Seattle Genetics Forward Looking Statement. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide. Enfortumab vedotin is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. About the Astellas and Seattle Genetics Collaboration Seattle Genetics and Astellas are co-developing enfortumab vedotin under a collaboration that was entered into in 2007 and expanded in 2009. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. Initial results from the trial were presented at the European Society of Medical Oncology (ESMO) 2019 Congress, and updated findings at the 2020 Genitourinary Cancers Symposium. Review our consolidated business results, forecasts and financial data, etc. Seattle Genetics and Astellas are co-developing enfortumab vedotin under a collaboration that was entered into in 2007 and expanded in 2009. About the Astellas and Seattle Genetics Collaboration . Under the collaboration, the companies are sharing costs and profits on a 50:50 basis … Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration Bothell, WA and Santa Monica, CA – June 9, 2011 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. This website is intended for U.S. residents only. Seattle Genetics Forward Looking Statements Certain statements made in this press release are forward looking, such as those, among others, relating to clinical development plans including the proposed phase 3 trial of enfortumab vedotin in combination with pembrolizumab as a potential treatment option for previously untreated metastatic urothelial cancer; the therapeutic potential of enfortumab vedotin including its possible safety, efficacy, and therapeutic uses, including in previously untreated metastatic urothelial cancer, and the potential FDA approval of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The Breakthrough Therapy designation was granted based on results from the dose-escalation cohort and expansion cohort A of the phase 1b/2 trial, EV-103 (NCT03288545), evaluating patients with locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy treated in the first-line setting with PADCEV in combination with pembrolizumab. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. BOTHELL, Wash., and TOKYO, December 2, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody … Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies … _____________________________1 American Society of Clinical Oncology. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide. Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals. About Seattle Genetics Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives. "We look forward to initiating a randomized phase 3 trial in patients with previously untreated locally advanced or metastatic urothelial cancer," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. By using this site, you accept our use of cookies as described in our privacy policy. There is no guarantee that the agent will receive regulatory approval or become commercially available for the uses being investigated. Feature Stories showcase the people and programs that bring to life the Astellas Way values and culture. http://gco.iarc.fr/tomorrow. For ADC programs solely developed and commercialized by Agensys /Astellas, Seattle Genetics is entitled to receive fees, milestones and royalties. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. About Enfortumab VedotinEnfortumab vedotin is an investigational ADC composed of an anti-Nectin-4 monoclonal antibody attached to a microtubule-disrupting agent, MMAE, using Seattle Genetics' proprietary linker technology. Seattle Genetics Forward Looking Statements Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide. Astellas participates in Access Accelerated. Under the collaboration, the companies are co-developing and have options to globally co-commercialize enfortumab vedotin. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide. The trial will be designed to evaluate the efficacy of the combination of enfortumab vedotin and pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial cancer. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.